|  |
| --- |
| **Supplementary Table 1: Treatment outcomes in other studies evaluating M1 and M2 MCA occlusions** |
| **Study** | **Groups** | **N** | **Recanalization****Rate % (n)** | **Good mRS % (n)** | **Mortality % (n)** | **Procedural Complications (%)** | **sICH % (n)** |
| **Our Study** | M1 | 145a | 81.7 (125/153) | 51 (74) | 20 (29) | 3.3 (5)b | 3.3 (5)c |
| M2 | 59 | 84.7 (50) | 55.9 (33) | 13.6 (8) | 5.1 (3) | 3.4 (2)c |
| Total | 204a | 82.5 (175/212) | 52.5 (107) | 18.1 (37) | 3.8 (8)b | 3.3 (7)c |
| **Coutinho 2016**[16]d e | M1 | 249 | 82 (193/235) | 56 (136/243) | 10 (25) | 4 (10) | 2 (5)f |
| M2 | 50 | 85 (34/40) | 60 (30) | 12 (6) | 6 (3) | 2 (1)f |
| Total | 299 | 82.5 (227/275) | 56.7(166/293) | 10.4 (31) | 4.3 (13) | 2 (6)f |
| **Dorn 2015** [12] | M1 | 104 | 76.0 (79) | 43.3 (45) | 21.2 (22) | 2.9%g | 5.8 (6)h |
| M2 | 15 | 93.3 (14) | 60 (9) | 6.7 (1) | 0 (0) | 6.7 (1)h |
| Total | 119 | 78.2 (93) | 45.3 (54) | 19.3 (23) | 2.5 (3)g | 5.9 (7)h |
| **Dorn 2016** [22]i | M1 | 76 | - | 40.5 (30) | - | - | - |
| M2 | 11 | - | 45.5 (5) | - | - | - |
| Totali | 124 | 78 | 37.9 (47) | 24.2 | 8.5% j | 13.1 (17)k |
| **Goyal 2016**[13]i e | M1 | 438 | - | 48.9 (214) | 14.6 (64) | - | - |
| M2 | 51 | - | 49 (25) | 15.7 (8) | - | - |
| Totali | 634 | 71 | 46 (291) | 15.3 (97/633) | - | 4.4 (28)l |
| **Lemmens 2016** [15]i d | M1  | 389 | 64.5 (251) | 43.7 (170) | 17.0 (66) | - | 5.1 (20)m |
| M2 | 131 | 51.1 (67) | 45.8 (60) | 15.3 (20) | - | 6.9 (9)m |
| Totali | 710 | 58.1 (413) | 41.7 (296) | 19.0 (135) | - | 6.2 (44)m |
| **Protto 2016** [11]i | M1 | 46 | 94 (43) | 63 (29) | 13 (6) | - | 7 (3)h |
| M2 | 22 | 77 (17) | 50 (11) | 14 (3) | - | 9 (2)h |
| Totali | 105 | 88 (92) | 57 | 14 (15) | - | 6 (6)h |
| **Shi 2010** [23] | M1 | 150 | 60 (90/150)n | 33.3 (46/138) | 32.9 (48/146) | 5.3 | 6.7 (10) p |
| M2 | 28 | 82.1 (23/28)n | 40.7 (11/27) | 25.9 (7/27) | 3.6 | 3.6 (1)p |
| Total | 178 | 63.5p | 34.5 | 31.8 | 5.1 | 6.2 (11)p |
| *Abbreviations: ECASS (European-Australasian acute Stroke Study), IVH (intra-ventricular hemorrhage), M1 (main middle cerebral artery trunk), M2 (first division of the middle cerebral artery), mRS (modified Rankin score), NIHSS (National Institutes of Health Stroke Scale), NR (not reported), PH (parenchymal hematoma), pH2 (parenchymal hematoma type 2), SAH (subarachnoid hemorrhage), sICH (symptomatic intracranial hemorrhage), TIMI (Thrombolysis in Myocardial Infarction)*a Total patients = 212, 8 loss to follow up from M1 group b Excluding non-flow limiting arterial dissectionc ICH + ≥ 4-point increase in NIHSS d Overlapping data from SWIFT and STAR studiese Overlapping data from SWIFT PRIME studyf Symptomatic ICH defined in each study: STAR: ECASS criteria, SWIFT: ICH + ≥ 4-point increase in NIHSS, SWIFT PRIME: Parenchymal hematoma or subarachnoid hemorrhage or intra-ventricular hemorrhage + ≥ 4-point increase in NIHSSg n=3; dissection (n=1), loss of device (n=1), thrombus loss (n=1)h Parenchymal Hematoma type 2; No definition of symptomatic hemorrhage providedi Included patients with internal carotid artery occlusionsj Subarachnoid hemorrhage (n=6), dissection (n=2), thrombus loss (n=1), loss of device (n=2) (total includes patients with internal carotid artery occlusions)k ECASS III criteria usedl Symptomatic ICH defined in each study: MR CLEAN: ICH + ≥ 4-point increase in NIHSS, ESCAPE: ICH + ≥ 2-point increase in NIHSS, EXTEND-IA: Parenchymal hematoma type 2 or subarachnoid hemorrhage + ≥ 4-point increase in NIHSS, SWIFT PRIME: Parenchymal hematoma or subarachnoid hemorrhage or intra-ventricular hemorrhage + ≥ 4-point increase in NIHSS, REVASCAT: Parenchymal hematoma type 2 + ≥ 4-point increase in NIHSS; total rate of parenchymal hematoma type 2 5.1% (32 / 629)m Symptomatic ICH defined in each study: DEFUSE 2: SITS MOST criteria, SWIFT: ICH + ≥ 4-point increase in NIHSS, STAR: ECASS criteria, IMS III: ICH with decline in neurological status and new or worsening neurological symptoms (≥4-point increase in NIHSS score from baseline was used as a guide)n TIMI Recanalizationp ECASS criteria used |